NCT06948487Recruiting
Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
A Prospective, Multi-center, Observational Study on the Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
Source: ClinicalTrials.gov · Last updated 17 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 12000 (estimated)
- First submitted
- 15 Apr 2025
- Start date
- 17 Jun 2025
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- NCT number
- NCT06948487
What you commit to
- Study type: Observational
- Planned participants: 12000
- From 17 Jun 2025 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
- Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
Who the study is looking for
- Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
- Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
- Subjects who present with at least one subjective symptom requiring medical treatment
- Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.
Age in the registry: 19 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Masong Kim Internal Medicine Clinic Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.